Publications by authors named "Tiffany Nong"
Next-generation sequencing of samples from patients with acute myeloid leukemia (AML) has revealed several driver gene mutations in adult AML. However, unlike other cancers, AML is defined by relatively few mutations per patient, with a median of 4-5 depending on subtype. In this review, we will discuss the most common driver genes found in patients with AML and focus on the most clinically relevant ones that impact treatment strategies.
View Article and Find Full Text PDFArticle Synopsis
- BTK inhibitors, especially the first-in-class ibrutinib, have significantly improved treatment for B cell lymphomas like chronic lymphocytic leukemia (CLL), but new options are emerging for better safety and efficacy.
- A noncovalent BTK inhibitor, pirtobrutinib, has recently been approved for tough-to-treat CLL cases, raising questions about its potential to replace covalent inhibitors in standard treatments.
- Ongoing advancements in BTK inhibitors and their degraders may reshape treatment strategies for B cell cancers and autoimmune diseases in the future, highlighting the evolving landscape of this field.